GenomOncology's Precision Oncology Platform (POP) powers our end-to-end clinical informatics solutions for cancer. Our POP houses our extensive set of complex rules, annotations, and ontologies to create a flexible, cross-functional augmented intelligence stack that allows users to move, convert, and interpret complex data sets. Our platform's APIs empower researchers and clinicians to extend the POP's knowledge to maintain their own curated repositories and to integrate our solutions into their existing precision oncology workflows.
OUR EXTENDABLE MODEL
Our biomarker capabilities with the POP not only enables the analysis of complex somatic variants, but also germline variants in order to support every aspect of your genomic testing and analysis needs.
Our POP can be used as a search engine to browse each of our knowledge sets. Users can also use our GO CLI tools and GO Connect to extract, transform, and load data into our POP so that their own curated content can be added to our database.
Interact with our POP through our pre-defined user interfaces (UI) or leverage our APIs for knowledge-driven matching, variant annotations, and more. Users can also use our command line interface to extract, transform, and load data into our POP models.
Our POP works"statelessly," enabling you to send requests to our APIs and get back a specific calculated output, or "statefully," enabling you to store, analyze, and track your clinical data.
SECURITY & INTEGRATION
Our POP can be utilized as the molecular plumbing that supports all of your precision oncology needs without the transfer of any Protected Health Information (PHI). We built a fully secure platform that is compliant with all HIPAA protections and can integrate with your existing security infrastructure.
OUR PLATFORM IN USE
Baylor uses our POP to support their comprehensive tests covering a broad spectrum of germline and somatic genetic disorders. Their genetics team is able to annotate and curate massive biomarker sets at rapid speeds.
Indiana University has integrated our clinical trial matching APIs into their existing Precision Health UI that enables them to send biomarker and disease information to our POP and receive clinical trial recommendations in return.
Genomic England is leveraging our POP as a key content driver to augment their 100,000 Genomes Project’s cancer program, with Vanderbilt University's My Cancer Genome content and the most relevant treatment information.